About Triumvira Immunologics
Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer.
Sectors & Market Categories
Company Details
Corporate & Operational Profile
Primary Industry
Biotech & Healthcare
Funding Stage
Series-A
Global Headquarters
San Francisco, United States
Team Size
11–50 employees
Tracked Since
Nov 16, 2026
Web & Domain Identity
Official Website
triumvira.com
Domain Registered Date
Undisclosed
Social & Network Presence
X / Twitter Profile
@Triumvirainc
(57 followers)
LinkedIn Corporate
Company Profile
Company Milestones & Timeline
- Capital Raise
Raised $45,000,000 · Series-A
Backed by B Capital
- Capital Raise
Raised $55,000,000 · Series-A
Backed by Leaps by Bayer
Investors & Backers
B Capital
Lead
Leaps by Bayer
Lead
ATEM Capital Fund LP
Bloom Burton & Co.
Centre for Commercialization of Cancer Immunotherapy
Multiple Myeloma Research Foundation
Myeloma Investment Fund
Northpond Ventures
Oceanpine Capital
Viva Biotech
Funding History
Series-A equity
· Mar 17, 2022
Round backers: B Capital
$45,000,000 startupintros.com
Series-A equity
· Aug 1, 2020
Round backers: Leaps by Bayer
$55,000,000 startupintros.com
Founders & Leadership
Andreas Bader
Chief Scientific Officer
Work email & phone locked
Unlock →
Jonathan Bramson
Founder
Work email & phone locked
Unlock →
Jon Irvin
Senior Vice President of Finance
Work email & phone locked
Unlock →
Paul Lammers
President & CEO
Work email & phone locked
Unlock →
Pedro Correa de Sampaio
Project Consultant
Work email & phone locked
Unlock →
Robert Williamson
President and CBO
Work email & phone locked
Unlock →
Sabine Chlosta
Chief Medical Officer
Work email & phone locked
Unlock →
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allTesorai
tesorai.com
Seed Nov 2026
Commit Biologics
commitbio.com
Seed Aarhus · Nov 2026
Human Biome
human-biome.com
Series-A Warsaw · Nov 2026
MedInTech
medintech.co.kr
Series-B Seoul · Nov 2026
Ace Padel
acepadel.com
Seed Bradenton, United States · Nov 2026
Mentix
mentix.world
Pre-Seed London, United Kingdom · Nov 2026